Login
Companies $FATE
$1.13 -$0.01 (0.82%) After hours
FATE THERAPEUTICS INC logo

FATE THERAPEUTICS INC

fatetherapeutics.com

What Do They Do?

Develops ready-to-use engineered T-cell and natural killer cell therapies for patients with autoimmune diseases and cancer.

How Do They Make Money?

Pharmaceutical collaborators pay upfront and for research and preclinical work under collaboration agreements; government grants also provide revenue. The company has not earned revenue from therapeutic product sales or royalties.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical companies collaborate with Fate on research, development and commercialization of cell therapy candidates; the Ono agreement covers joint development of candidates.

Do Revenues Turn Into Profits?

No. It lost $136.3M in FY2025.

Operating income, FY2025
−2222% of revenue
▲ +30% (Loss) vs FY2024 (−$210.3M, −1543%)
Net income, FY2025
−2051% of revenue
▲ +27% (Loss) vs FY2024 (−$186.3M, −1366%)
Free cash flow, FY2025
−1686% of revenue
▲ +9% (Loss) vs FY2024 (−$123.6M, −907%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $1.7M in Q3 FY2025

Shrinking. Revenue fell 88% in 4 years, from $55.8M in FY2021 to $6.6M in FY2025, about 41% a year.

Autoimmune focus The older report described its pipeline for cancer and autoimmune disorders; the latest states an initial focus on autoimmune diseases and cancer while still describing cancer programs.

Who Do They Compete With?

Competes with Adicet Bio, Allogene Therapeutics, Arcellx, Artiva Biotherapeutics, AstraZeneca, Autolus Therapeutics, Bristol-Myers Squibb, Cabaletta Bio, Caribou Biosciences, Cartesian Therapeutics, Cellectis, Century Therapeutics, CRISPR Therapeutics, Cullinan Therapeutics, ImmunityBio, Janssen Biotech, Kyverna Therapeutics, Legend Biotech, Lyell Immunopharma, and Kite Pharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support